adlainortye.com (ANL): Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization

Corporate company logo of Adlai Nortye Ltd (ANL)

Adlai Nortye Ltd. (ANL) develops unique combination therapies to combat resistant tumors, addressing the most complex challenges of modern medicine. The business relies on an exclusive FDA authorization for Buparlisib, maintaining a monopoly position in the treatment of advanced head and neck cancer. Subject to standard environmental norms, the EV/EBITDA ratio stands at 0.00. The company's stock price action is presented below.

Adlai Nortye - ANL Company Value to EBITDA (period 11/23/2025 - 11/15/2026)

Adlai Nortye Ltd - analytical breakdowns and key metrics (ANL)

- stock price and consensus target price:
Summary company analytics:Adlai Nortye Ltd. ANL
Product sample of Adlai Nortye

For Adlai Nortye Ltd. (ANL), whose operations focus on capital-intensive clinical trials of oncology drugs and the maintenance of high-tech laboratories, business valuation accounting for debt load is critically important. By analyzing the EV/EBITDA multiple, an investor compares the total value of assets and liabilities with operating profit, which allows for the determination of the company's real value relative to its ability to generate cash flow.

Competitors of Adlai Nortye Ltd.

BeiGene Oncology - Enterprise Value to EBITDA Ratio|HALO - Enterprise Value to EBITDA Ratio|RVMD: Enterprise Value to EBITDA Ratio|AAPG - EV/EBITDA Multiple|CG Oncology Corp (CGON) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|UroGen - Business Value to Operating Income Before Depreciation|BCAX (Bicara Therapeutics Inc) - EV/EBITDA Multiple|Company Value to EBITDA personalis.com PSNL|EV/EBITDA Multiple ERAS|Delcath Systems - Enterprise Value to Operating Income Before Depreciation|Y-mAbs Therapeutics Inc - Enterprise Value to EBITDA Ratio|EV/EBITDA Multiple Aura Corp AURA|CADL - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Accuray (ARAY) - Enterprise Value to EBITDA Ratio|SLS: EV/EBITDA Multiple|Actuate Therapeutics (ACTU) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio CTOR|HURA: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Protara Therapeutics (TARA)|Enterprise Value to Operating Income Before Depreciation Ratio FATE|EV/EBITDA Multiple WHWK (aadibio.com)|Enterprise Value to Operating Income Before Depreciation Ratio TCRX (TScan)|CSBR - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Business Value to Operating Income Before Depreciation XBIT (XBiotech Inc)|cel-sci.com (CVM) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio OSTX (OS Therapies Incorporated)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Radiopharm Theranostics Ltd|Company Value to EBITDA Artiva Biotherapeutics ARTV|EV/EBITDA Multiple VERU|TPST - Company Value to EBITDA|EV/EBITDA Multiple XLO (Xilio Therapeutics)|RENB - Enterprise Value to EBITDA Ratio|muraloncology.com - EV/EBITDA Multiple|KAPA - EV/EBITDA Multiple|OKUR: EV/EBITDA Multiple|Company Value to Operating Income Before Depreciation Ratio GDTC (CytoMed Therapeutics Ltd)|CRIS (curis.com) - EV/EBITDA Multiple|Apollomics, Inc. (APLM) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to EBITDA Ratio THAR (Tharimmune, Inc.)|ADVB (Advanced Biomed) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple GNPX (Genprex Inc)|calidibio.com (CLDI) - Company Value to EBITDA|sunshinebiopharma.com - EV/EBITDA Multiple|Company Value to EBITDA Xenetic Biosciences, Inc.|SLRX (Salarius Pharmaceuticals) - Enterprise Value to EBITDA Ratio|Enterprise Value to EBITDA Ratio Purple Biotech Ltd.|AONC (American Oncology Network Inc) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio BeOne Medicines (BGNE)|EV/EBITDA Multiple CKPT|ELEV - Company Value to EBITDA|iCAD Inc. - Enterprise Value to EBITDA Ratio|IKNA: Enterprise Value to Operating Income Before Depreciation|Notable Labs Ltd - EV/EBITDA Multiple|Business Value to Operating Income Before Depreciation VIRX (Viracta Therapeutics Inc.)|MorphoSys AG (MOR) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio NAYA Biosciences|AAPGV (ascentage.com) - EV/EBITDA Multiple